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Drug resistance mutations emerge in genetic sequences of HIV through selective pressure during antiretroviral
therapy. Drug resistances can be transmitted and reduce the chances of long-lasting successful treatment.
Phylogenetic methods have been used to estimate the parameters shaping the emergence of drug resistance
and spread of resistant viruses. In this review we discuss the examples of use of phylogenetic methods in
studies of drug resistance mechanisms in HIV.
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The clinical epidemiology of HIV drug resistance1
The clear majority of publications on HIV drug resistance em-2
anate from the resource rich world, including those pertaining to3
the clinical epidemiology of resistance. Whilst there remain im-4
portant lessons to be drawn to understand the spread of drug re-5
sistance in resource limited settings, it is worth comparing these6
settings in considering drivers of drug resistance (Table 1). We7
witnessed high levels of resistance in treated and untreated in-8
dividuals in the 1990’s and early 2000’s in those settings with9
access to therapy. To a large extent, this rise was associated with10
what is now recognised to be suboptimal therapy – limited drug11
classes, pill burden, toxicities, late initiation of therapy – to-12
gether with continuing transmission in high risk communities.13
Since that time, the availability of more than 25 antiretroviral14
(ARV) drugs across five classes, individualised therapy includ-15
ing the use of resistance testing, and simplified regimens have16
led to a dramatic reduction in resistance in these settings [1].17
Indeed, some predictions at the time of ever increasing levels of18
resistance [2] have not been bourne out [3]. By contrast, we are19
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observing the opposite phenomenon in resource limited settings,20
where the burden of infection is greatest [4]. Table 1 identifies21
some of the drivers of such high levels of resistance.22
How can we better understand this phenomenon, and develop23
tools for predicting future trends? The overall population bur-24
den of resistance is contributed to both by the emergence of re-25
sistance in treated individuals, as well as by transmission of re-26
sistance. It is self-evident that the dynamics of the epidemic it-27
self must be considered in modelling future spread of resistance28
– in other words, the proportion of infected individuals diag-29
nosed and receiving treatment, as well as the ongoing incidence30
of infection must be considered. From an overall health burden31
and policy perspective, there is a big difference between a trans-32
mitted drug resistance (TDR) rate of 15% within a setting of33
population HIV incidence of 2%, compared to a TDR rate of 5%34
in a population with 6% incidence. This contrast is exemplified35
in modelling approach undertaken by Phillips and colleagues,36
which addresses the likely impact of a widespread HIV test-37
ing and treatment strategy within the South African epidemic.38
Based on a 2012 prevalence of TDR of < 10%, their model39
suggests that over a 20-year period of such a test and treat strat-40
egy, overall incidence of infection would be reduced by 50%.41
Nevertheless, by that time, up to 30% of new infections would42
be with drug resistant virus [5]. For this reason, programmes on43
surveillance of drug resistance need to be placed into a wider44
clinical epidemiology of the epidemic in question.45
It is also important to consider the developing use of an-46
tiretrovirals for pre-exposure prophylaxis (PrEP). Following the47
PROUD and IPER-GAY study results [6, 7], there is a strong48
push for rollout of PrEP within high risk populations in resource49
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poor settings. The first case of PrEP failure due to resistance has50
now been reported [8]. Abbas et al. [9] modelled the potential51
impact of preexposure prophylaxis (PrEP) on HIV transmission52
and drug resistance in South Africa. They predicted that com-53
bined ART + PrEP over 10 years would reduce the number of54
infections ( 35Supervie et al. performed two modeling studies55
on rolling out of PrEP: in San Francisco (i.e., in a resource-rich56
country) [10] and in Botswana (resource-limited) [11]. They57
showed that if PrEP is widely used in a “high-risk” community58
in San Francisco the number of infections as well as the num-59
ber of transmitted ART resistance is likely to decrease (if risk60
behavior does not increase significantly). In contrast, the intro-61
duction of PrEP interventions in Botswana is likely to lead to62
increase of transmitted ART (while decreasing the overall num-63
ber of infections). This occurs because the level of ambient re-64
sistance is higher in San Francisco than in Botswana due to a65
longer treatment history. The differences in the results obtained66
in the studies by Abbas et al. and by Supervie et al. draw our67
attention to the importance of taking into account the assump-68
tions that are made, e.g. the initial levels of resistance when the69
rollout begins.70
Several studies have utilised phylogenetics together with de-71
tailed clinical and epidemiological data to explore the origin of72
incident infections. Fisher et al. [12] demonstrated that up to73
30% of new infections were from individuals in the highly infec-74
tious primary stage of infection. Brenner et al. [13] used phylo-75
genetic clustering analysis of Quebec HIV-infected population76
to show that early infections may account for a major propor-77
tion of onward transmissions. This approach was expanded to78
the ATHENA cohort in the Netherlands [14] to show that both79
primary and undiagnosed infections together accounted for the80
bulk of new infections. By contrast, few transmissions came81
from those in care and on antiretroviral therapy. However, the82
incidence of transmissions from treated patients bearing not yet83
detected resistances due to poor monitoring (a typical situation84
in developing countries) remain to be estimated.85
Against this background, what is the potential role of phy-86
logenetics in enhancing our understanding of emergence and87
spread of drug resistance? Firstly, who are the main transmitters88
of drug resistance, and are they receiving antiretroviral therapy89
or not? Secondly, what is the contribution of transmission dur-90
ing acute infection to spread of drug resistance? Thirdly, what91
is the persistence of drug resistant strains of virus within the92
population? Lastly, as PrEP becomes widespread, can we iden-93
tify emergence and transmission of resistant strains from those94
infected whilst receiving PrEP?95
Phylogenetics and drug resistance96
HIV viruses rapidly accumulate genetic variation because of97
short generation times and high mutation rates. Phylogenetic98
Table 1. Drivers of high levels of resistance.
Characteristics Resource Resource Impact on
rich limited population drug
countries countries resistance in
resource limited
settings
Calendar time of 1980’s 2000’s ↓
ARV availability
Treatment para- Mono-, to
digm from time dual- to triple Triple therapy ↓
of ARV availability therapy
Availability of
second and third Yes No ↑
line regimens
Single dose NVP No Yes ↑
for PMTCT
VL monitoring Extensive Limited ↑
availability
Incidence and Low High ↑
prevalence
ARV, Antiretroviral drugs; NVP, Nevirapine (Viramune); PMTCTC,
Prevention of mother-to-child transmission; VL, viral load.
inference methods use these variations for reconstruction of99
phylogenies (phylogenetic trees) from contemporary sequenc-100
ing data. The root of the tree represents the ancestral lineage,101
and the tips correspond to the virus sequences at the moment of102
sampling. Going from the root to the tips corresponds to moving103
forward in time. When a lineage splits (speciation), it is repre-104
sented as a branching node of the phylogeny. When the sam-105
pling is dense such a split can be interpreted as a virus transmis-106
sion infecting a new individual, and the whole tree is an approx-107
imation of the transmission tree [15].108
To access the robustness of the reconstructed tree the sup-109
port values on its branches can be calculated using statistical110
methods, such as bootstrap [16]. These values tend to decrease111
when going back in history, from tips to the root. In order to112
remove the uncertain data from the study, often genetic clusters113
are used instead of the whole tree. Such clusters correspond to114
the well-supported subtrees that contain sequences closely re-115
lated to each other and distant from the rest of the tree (see [17]116
for an overview of genetic clustering methods). A cluster of se-117
quences that also share a common trait values (e.g. geographic118
location, risk group, presence of a given resistance mutation) is119
called a phylotype [18]. The branch lengths in genetic clusters120
are typically short, and therefore a cluster can be interpreted as121
representing a recent outbreak, as for example, in a situation122
when a virus acquires a DRM under drug selective pressure and123
the patient starts transmitting the resistant virus. The subtree in-124
cluding this patient, individuals infected by him/her, and those125
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infected by them, would form a resistance cluster if they are126
sampled before their virus strains diverge significantly. The root127
of the cluster would correspond to the first transmission event.128
Viral phylodynamics is defined as the study of how epidemi-129
ological, immunological, and evolutionary processes act and130
potentially interact to shape viral phylogenies [19, 20]. Phylo-131
dynamics methods have been used to estimate the parameters132
shaping the emergence of drug resistance and spread of resis-133
tant viruses, such as, for example, the persistence time of drug134
resistance mutations (DRMs) in the untreated population.135
Wensing et al. [21] used phylogenetic reconstruction and136
genetic clustering to study the persistence of DRMs in HIV-137
infected treatment-naı¨ve patients from 19 countries across Eu-138
rope. They found a significant difference in the level of baseline139
resistance between recently infected patients (13.5%) and pa-140
tients infected for more than one year (8.7%).141
The origin of transmitted drug resistance has been addressed142
by several groups. Yerly et al. [22] reconstructed HIV transmis-143
sion clusters in Geneva using phylogenetic analysis, and showed144
that newly diagnosed HIV infections are a significant source145
of onward transmission, notably of resistant strains. Audelin et146
al. [23] studied TDR among newly diagnosed HIV-1 individuals147
in Denmark, and concluded that TDR isolates mostly originate148
from patients failing therapy. The same conclusion was reached149
by Lewis et al. [24] using ≈ 2,000 patients from London, pre-150
dominantly men who have sex with men (MSM), using a similar151
transmission-cluster-based approach.152
Hue´ et al. [25], and later Mourad et al. [26] obtained differ-153
ent results while studying HIV-1 transmission in the UK. Hue´ et154
al. studied treatment-independent viral clusters with DRMs and155
demonstrated that sustainable reservoirs of resistance persist in156
the HIV-1-infected population through continuous transmission157
of resistant viruses among treatment-naı¨ve individuals. Mourad158
et al. used a parsimony-based approach [27] to extract phylo-159
types of sequences, the most recent common ancestor of which160
was bearing a resistant mutation that is still shared by the ma-161
jority of the sequences in the phylotype. Once dated and com-162
bined with the treatment-naı¨ve/experienced status of those rep-163
resented by the sequences, these phylotypes were used to zoom164
on the most readable parts of the phylogeny and compute simple165
statistics which are immediately accessible from the annotated166
tree; for example, the number of naı¨ve-to-naı¨ve transmissions of167
DRMs, or the fraction of extant sequences having lost the ances-168
tral resistance. The simplicity of the method makes it computa-169
tionally very efficient. It was applied to a large set of ≈ 25,000170
HIV-1 subtype B sequences from the UK, where it showed171
that around 70% of transmitted drug-resistance had a treatment-172
naı¨ve source. In this population, the most commonly transmitted173
mutations were L90M in the protease gene and K103N, T215D174
and T215S in reverse transcriptase. Moreover, reversion to wild175
type occurred at a low frequency and drug-independent reser-176
voirs of resistance have persisted for up to 13 years.177
These conclusions are very close to those of Drescher et178
al. [28] who studied the transmission of resistances among179
MSM in the Swiss HIV Cohort. Their method was different180
as they did not reconstruct the ancestral resistance status of the181
sequences; but they also extracted well supported transmission182
clusters from a large sequence phylogeny, and searched for the183
potential sources of the resistances observed in these clusters.184
The discrepancy between the results obtained by Mourad et185
al. [26] and Drescher et al. [28], and those obtained by Audelin186
et al. [23] and Lewis et al. [24], is most likely attributable to the187
size of the data sets, from ≈ 2,000 in [24] published in 2008,188
to ≈ 25,000 in [26] published in 2015. Moreover, the sampling189
density is of prime importance (> 50% in [26] and [28]), be-190
cause to demonstrate naı¨ve-to-naı¨ve TDR relatively large resis-191
tance clusters with no or little missing data are needed. When192
the ratio of missing data is high, it is not possible to conclude193
on the origin of the transmission for isolated drug-naı¨ve patients194
harbouring DRMs.195
Conclusions196
In summary, we argue for building phylogenetics into a more197
detailed epidemiological surveillance of HIV drug resistance.198
With an ever reducing cost of genetic sequencing, there is a199
move to generate full length HIV sequences [29]. This has the200
capacity to increase the phylogenetic resolution due to a longer201
sequence length. Through a large simulated dataset, we have202
shown that the accuracy of trees was nearly proportional to the203
length of sequences,with gag-pol-env datasets showing best per-204
formance compared to the partial pol sequences commonly cre-205
ated through drug resistance testing [30]. An added advantage206
of extended sequencing is the ability to capture integrase in-207
hibitor resistance. Care must be taken in the sampling frame in208
the context of HIV prevalence, to produce realistic estimates.209
This will facilitate a better understanding of the drivers of resis-210
tance spread, the source of transmitted resistance, and how this211
is changing over time in the face of antiretroviral rollout.212
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